Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Indiana University
mi
from
Indianapolis, IN
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
University of Kansas Medical Center
mi
from
Kansas City, KA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Parexel International
mi
from
Baltimore, MD
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Parexel International
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
BJC Medical Group (Missouri Baptist Medical Center)
mi
from
St. Louis, MO
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
BJC Medical Group (Missouri Baptist Medical Center)
mi
from
St. Louis, MO
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Univ of Rochester Medical Center
mi
from
Rochester, NY
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Rhode Island Hospital
mi
from
Providence, RI
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
New Orleans Center for Clinical Research (NOCCR)
mi
from
Knoxville, TN
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
New Orleans Center for Clinical Research (NOCCR)
mi
from
Knoxville, TN
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Fletcher Allen Health Care
mi
from
Burlington, VT
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Virginia Mason Medical Center (VMMC)
mi
from
Seattle, WA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Virginia Mason Medical Center (VMMC)
mi
from
Seattle, WA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Multiple Sclerosis Center, Swedish Neuroscience Institute
mi
from
Seattle, WA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Multiple Sclerosis Center, Swedish Neuroscience Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome
Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome
Status: Enrolling
Updated:  3/6/2014
OSF St. Francis Medical Center
mi
from
Peoria, IL
Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome
Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome
Status: Enrolling
Updated: 3/6/2014
OSF St. Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI)
Behavioral and Neuroimaging Changes After Cognitive Rehab in TBI and MCI
Status: Enrolling
Updated:  3/7/2014
Atlanta VA Medical and Rehab Center, Decatur
mi
from
Decatur, GA
Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI)
Behavioral and Neuroimaging Changes After Cognitive Rehab in TBI and MCI
Status: Enrolling
Updated: 3/7/2014
Atlanta VA Medical and Rehab Center, Decatur
mi
from
Decatur, GA
Click here to add this to my saved trials
Steroids Versus Gabapentin
Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy
Status: Enrolling
Updated:  3/10/2014
Johns Hopkins
mi
from
Baltimore, MD
Steroids Versus Gabapentin
Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy
Status: Enrolling
Updated: 3/10/2014
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Steroids Versus Gabapentin
Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy
Status: Enrolling
Updated:  3/10/2014
Naval Hospital-San Diego
mi
from
San Diego, CA
Steroids Versus Gabapentin
Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy
Status: Enrolling
Updated: 3/10/2014
Naval Hospital-San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Steroids Versus Gabapentin
Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy
Status: Enrolling
Updated:  3/10/2014
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Steroids Versus Gabapentin
Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy
Status: Enrolling
Updated: 3/10/2014
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
TRI102-ADD-001 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
TRI102-ADD-001 in the Treatment of Children With ADHD: A Laboratory Classroom Study
Status: Enrolling
Updated:  3/10/2014
Newport Beach Clinical Research Associates, Inc.
mi
from
Newport Beach, CA
TRI102-ADD-001 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
TRI102-ADD-001 in the Treatment of Children With ADHD: A Laboratory Classroom Study
Status: Enrolling
Updated: 3/10/2014
Newport Beach Clinical Research Associates, Inc.
mi
from
Newport Beach, CA
Click here to add this to my saved trials
TRI102-ADD-001 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
TRI102-ADD-001 in the Treatment of Children With ADHD: A Laboratory Classroom Study
Status: Enrolling
Updated:  3/10/2014
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
TRI102-ADD-001 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
TRI102-ADD-001 in the Treatment of Children With ADHD: A Laboratory Classroom Study
Status: Enrolling
Updated: 3/10/2014
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
TRI102-ADD-001 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
TRI102-ADD-001 in the Treatment of Children With ADHD: A Laboratory Classroom Study
Status: Enrolling
Updated:  3/10/2014
Duke Univ Med Ctr
mi
from
Durham, NC
TRI102-ADD-001 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
TRI102-ADD-001 in the Treatment of Children With ADHD: A Laboratory Classroom Study
Status: Enrolling
Updated: 3/10/2014
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
TRI102-ADD-001 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
TRI102-ADD-001 in the Treatment of Children With ADHD: A Laboratory Classroom Study
Status: Enrolling
Updated:  3/10/2014
Bayou City Research, Ltd.
mi
from
Houston, TX
TRI102-ADD-001 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
TRI102-ADD-001 in the Treatment of Children With ADHD: A Laboratory Classroom Study
Status: Enrolling
Updated: 3/10/2014
Bayou City Research, Ltd.
mi
from
Houston, TX
Click here to add this to my saved trials
TRI102-ADD-001 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
TRI102-ADD-001 in the Treatment of Children With ADHD: A Laboratory Classroom Study
Status: Enrolling
Updated:  3/10/2014
Westex Clinical Investigation
mi
from
Lubbock, TX
TRI102-ADD-001 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
TRI102-ADD-001 in the Treatment of Children With ADHD: A Laboratory Classroom Study
Status: Enrolling
Updated: 3/10/2014
Westex Clinical Investigation
mi
from
Lubbock, TX
Click here to add this to my saved trials
Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection
Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection
Status: Enrolling
Updated:  3/10/2014
Brigham and Women's Hosp
mi
from
Boston, MA
Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection
Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection
Status: Enrolling
Updated: 3/10/2014
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Ankle Robotics Training After Stroke
Ankle Robotics Training After Stroke: Effects on Gait and Balance
Status: Enrolling
Updated:  3/11/2014
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Ankle Robotics Training After Stroke
Ankle Robotics Training After Stroke: Effects on Gait and Balance
Status: Enrolling
Updated: 3/11/2014
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Click here to add this to my saved trials
Delirium in Mechanically Ventilated Patients
An Assessment of Delirium in Mechanically Ventilated Patients Undergoing Daily Awakening From Sedation
Status: Enrolling
Updated:  3/12/2014
University of Chicago
mi
from
Chicago, IL
Delirium in Mechanically Ventilated Patients
An Assessment of Delirium in Mechanically Ventilated Patients Undergoing Daily Awakening From Sedation
Status: Enrolling
Updated: 3/12/2014
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Analgesic Efficacy and Safety of Voltaren Gel (1% Diclofenac Sodium) Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness
Randomized, Double-Blind, Within-Subject, Proof of Concept Study to Assess the Analgesic Efficacy and Safety of Voltaren Gel (1% Diclofenac Sodium) Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness
Status: Enrolling
Updated:  3/13/2014
Lotus ClinicalResearch,LLC
mi
from
Pasadena, CA
An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Analgesic Efficacy and Safety of Voltaren Gel (1% Diclofenac Sodium) Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness
Randomized, Double-Blind, Within-Subject, Proof of Concept Study to Assess the Analgesic Efficacy and Safety of Voltaren Gel (1% Diclofenac Sodium) Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness
Status: Enrolling
Updated: 3/13/2014
Lotus ClinicalResearch,LLC
mi
from
Pasadena, CA
Click here to add this to my saved trials
Combining Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors With Attentional Deficits
Combining Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors With Attentional Deficits
Status: Enrolling
Updated:  3/18/2014
Spaulding Rehabilitation Hospital
mi
from
Boston, MA
Combining Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors With Attentional Deficits
Combining Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors With Attentional Deficits
Status: Enrolling
Updated: 3/18/2014
Spaulding Rehabilitation Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
HOPE Research Institute
mi
from
Phoenix, AZ
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
HOPE Research Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Catalina Research Institute
mi
from
Chino, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Catalina Research Institute
mi
from
Chino, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
ATP Clinical Research, Inc.
mi
from
Costa Mesa, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
ATP Clinical Research, Inc.
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Radiant Research
mi
from
Santa Rosa, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Radiant Research
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Research Center for Clinical Studies, Inc.
mi
from
Norwalk, CT
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Research Center for Clinical Studies, Inc.
mi
from
Norwalk, CT
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Chase Medical Research, LLC
mi
from
Waterbury, CT
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Chase Medical Research, LLC
mi
from
Waterbury, CT
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Brain Matters Research
mi
from
Delray Beach, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Brain Matters Research
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
MD Clinical
mi
from
Hallandale Beach, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
MD Clinical
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Galiz Research
mi
from
Miami Springs, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Galiz Research
mi
from
Miami Springs, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Renstar Medical Research
mi
from
Ocala, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Renstar Medical Research
mi
from
Ocala, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Compass Research LLC
mi
from
Orlando, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Princeton Medical Institute
mi
from
Princeton, NJ
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Princeton Medical Institute
mi
from
Princeton, NJ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Memory Enhancement Center Of Nj, Inc.
mi
from
Toms River, NJ
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Memory Enhancement Center Of Nj, Inc.
mi
from
Toms River, NJ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Brooklyn Medical Institute
mi
from
Brooklyn, NY
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Brooklyn Medical Institute
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Advanced Bio-Behavioral Sciences, Inc
mi
from
Elmsford, NY
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Advanced Bio-Behavioral Sciences, Inc
mi
from
Elmsford, NY
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
University of Rochester Medical Center at MCH
mi
from
Rochester, NY
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
University of Rochester Medical Center at MCH
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Summit Research Network
mi
from
Portland, OR
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Summit Research Network
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Grayline Clinical Drug Trials
mi
from
Wichita Falls, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Grayline Clinical Drug Trials
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
The Memory Clinic
mi
from
Bennington, VT
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
The Memory Clinic
mi
from
Bennington, VT
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
The University of California Irvine
mi
from
Orange, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
The University of California Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Meridien Research
mi
from
Brooksville, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Meridien Research
mi
from
Brooksville, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Social Psychiatry Research Institute
mi
from
Brooklyn, NY
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Social Psychiatry Research Institute
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Columbus Research and Wellness Institute
mi
from
Columbus, OH
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Columbus Research and Wellness Institute
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
FutureSearch Trials of Dallas, LP
mi
from
Dallas, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
FutureSearch Trials of Dallas, LP
mi
from
Dallas, TX
Click here to add this to my saved trials